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TDP-43 mislocalization and aggregation are implicated in the pathogenesis of ALS and FTLD-U. Valosin
containing protein (VCP) mutations also lead to TDP-43 deposition, resulting in Inclusion Body Myopathy,
Paget disease, and Frontotemporal Dementia (IBMPFD). In this issue of Neuron, Johnson et al. used
whole-exome capture to identify VCP mutations in familial ALS. This extends the VCP phenotype to include
motor neuron degeneration and provides another molecular tool to explore neurodegeneration disease
mechanisms underlying the TDP-43 proteinopathies.Amyotrophic lateral sclerosis (ALS) is one
of the most feared adult-onset illnesses in
man (reviewed in Leigh and Wijesekera,
2010). Previously known as ‘‘the creeping
paralysis,’’ it declares its presence with
focal muscular weakness, most com-
monly in one limb, and relentlessly
spreads to affect all muscle groups,
depriving patients of the ability to walk,
talk, and care for themselves. No thera-
pies significantly alter the disease course,
and death due to respiratory failure
occurs on averagewithin 3 years of symp-
tom onset. As a result, ALS is the most
common reason that people seek eutha-
nasia. ALS affects all populations, and
the life-time risk in people of European
ancestry is around 1 in 400. Ninety-five
percent of cases are sporadic (SALS),
but 5% of cases have an affected first-
or second-degree relative and are consid-
ered familial (FALS). The clinical diagnosis
of ALS is based on signs of progressive
upper and lower motor neuron dysfunc-
tion. Evidence of mild frontal lobe involve-
ment can be detected in 30% of cases,
and in3%of cases ALS is accompanied
by marked behavioral changes and
language deficits indicative of frontotem-
poral lobar dementia (FTLD). The pheno-
types of SALS and FALS cases are clini-
cally indistinguishable, and the link to
FTLD has been made through many
neurophysiological, imaging, and genetic
studies.
Molecular proof that ALS and FTLD
represent two ends of a phenotypic spec-
trum came from pathological studies that
identified transactivation response DNA812 Neuron 68, December 9, 2010 ª2010 Elsbinding protein (TDP-43) as the major
constituent of ubiquitinated neuronal cy-
toplasmic inclusions (NCIs) in > 90% of
ALS and 60% of FTLD cases (Neumann
et al., 2006), subsequently labeled as the
‘‘TDP-43 proteinopathies’’ (reviewed in
Mackenzie et al., 2010). TDP-43 is a
predominantly nuclear protein that regu-
lates RNA transcription, splicing, and
transport as well as micro-RNA biogenei-
sis. In FTLD and ALS cases, TDP-43
protein is lost from the nucleus and
accumulates in massive amounts in the
cytoplasm, forming detergent-resistant
inclusions that are heavily phosphorylated
and ubiquitinated. It is not yet clear
whether neurodegeneration is initiated
by a loss of nuclear TDP-43 function, a
toxic gain of function in the cytoplasm,
or a combination of the two.
Although many genetic variants have
been associated with sporadic ALS,
mutations in only three genes have been
firmly linked in autosomal-dominant
classical ALS kindreds: Cu/Zn superoxide
dismutatse (SOD1 20% of FALS),
TARDBP (1%–4%), and fused in sarcoma
(FUS, 2%–4%) (reviewed in Lagier-Tour-
enne et al., 2010). Interestingly, although
TDP-43 deposition is the hallmark of
ALS pathology in 90% of cases, it is
absent from SOD1 and FUS mutant
cases, indicating that their pathogenic
pathways appear distinct. This may
explain why therapies effective in mutant
SOD1 cellular and animal models did not
work in ALS patients who predominantly
have a TDP-43 proteinopathy. Mutations
in the TARDBP that are known to beevier Inc.neurotoxic in vivo and are associated
with TDP-43 pathology in ALS have
been identified in sporadic and familial
ALS (Sreedharan et al., 2008). The identi-
fication of FUS mutations is particularly
important as FUS is a functional homolog
of TDP-43, playing a key role in RNA pro-
cessing and micro-RNA biogenesis.
Similar to TDP-43, ALS patients with FUS
mutations also develop large cytoplasmic
aggregates within spinal motor neurons
and lose nuclear FUS (Vance et al.,
2009; Kwiatkowski et al., 2009).
In retrospect, VCP was a very good
candidate gene for screening in ALS but
it was not biology that led the authors
to discover the mutations, it was two
emerging technologies—exon capture
and massive parallel sequencing (John-
son et al., 2010). Most pathogenic muta-
tions are within the 1% of the genome
that encodes exons and result in changes
to the amino acid sequence of proteins.
Using commercially available CGH oligo-
mers, they were able to capture, se-
quence, and align 76%–80% of the
known exome. The Illumina sequencing
platform exploits a powerful microscope
and computer that is able to observe
millions of short DNA fragments being
synthesized, base by base, in real time.
These short DNA sequences can be
aligned to the reference human genome,
allowing variants to be identified.
The authors started by sequencing the
exome in two members of an auto-
somal-dominant Italian ALS kindred. After
filtering for known SNPs from the 1000




























Figure 1. Ubiquitinated TDP-43 Inclusions in the Neuronal Cytoplasm and Nucleus Are the
Pathological Hallmark of ALS and FTLD-U
Defective clearance of TDP-43 aggregates can arise due to mutation in three genes: TARDBP mutation
may increase cytoplasmic levels of TDP-43 and promote aggregation, PGRNmutations inhibit maturation
of the autophagosome, while VCP mutations inhibit TDP-43 degradation by the autophagy and proteaso-
mal pathways. The common pathology and clinical phenotype of ALS and FTLD-U clearly implicates
TDP-43 misaccumulation in their pathogenesis.
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insertions and deletions that were shared
by both affected individuals. Sanger se-
quencing these variants in an additional
affected family member and comparing
them to 200 controls narrowed the search
down to just four variants within regions of
genomic linkage. Themost obvious candi-
date was the heterozygous c.961G>A
nucleotide change, predicted to substi-
tute an arginine for glutamine at position
191 (R191Q) in the valosin-containing
protein.
The authors proceeded to sequence all
exons of VCP in 210 index FALS and 78
pathologically proven cases detecting
four more cases with VCP mutations
(another R191Q, R159G, D592N, and
R155H) that were not present in 1589
controls. All of the mutations were de-
tected in familial cases and none in the
73 sporadic cases sequenced. One ALS
patient with a R155H mutation had
TDP-43 and ubiquitin-positive NCIs, con-
firming the pathological diagnosis of ALS.
They conclude that VCP mutations cause
the mislocalization of TDP-43 within
motor neurons in the spinal cord that
results in neurodegeneration.Muscle wasting due to IBM can be
mistaken for ALS. Electromyography in
IBM cases can suggest denervation, so is
this a case of mistaken identity? Several
of the authors are highly experienced
neurologists who elicited signs of upper
and lower motor neuron degeneration.
The rapidly progressive disease course
leading to respiratory failure is not seen
with IBM. Following up the Italian R191Q
family, it was discovered that one parent
of the index case did have IBM, Paget’s,
and FTLD. One ALS patient from the
R159H kindred also had FTD and another
had Paget’s, which might have raised
suspicions about VCP. Finally the R155H
mutationwasdetected inaknown IBMPFD
kindred. Four out of the five kindreds,
however, had individuals with a pure ALS
phenotype, which suggests that features
of IBM,FTD,orPaget’s (andserumAlkaline
Phosphatase measurements) should be
sought in all patients and their relatives.
The question remains as to whether
TDP-43 mislocalization and aggregation
is mechanistic or just a bystander
phenomenon? TDP-43 is predominantly
nuclear in healthy myocytes; however,
large TDP-43 and ubiquitin immunoreac-Neuron 68,tive cytoplasmic inclusions were abun-
dant in all five muscle biopsies of VCP
mutation-positive IBMPFD cases and in
21/27 sporadic IBM cases (Weihl et al.,
2008). Western blots of muscle tissue
revealed much higher levels of TDP-43
deposition and a higher-molecular-
weight band (as seen in FTLD) that was
absent from controls.
Striking cytoplasmic mislocalization
and aggregation of TDP-43 was also
described in the frontal and temporal
lobes of patients with VCP mutations
and IBMPFD (Neumann et al., 2007).
Detergent-resistant phosphorylated and
ubiquitinated forms of TDP-43were iden-
tified on western blot, characteristic of
other FTLD-U cases, but the 25 kDa
C-terminal fragment was much less
evident. Intriguingly, TDP-43 and ubiqui-
tin-positive lentiform (lens shaped) intra-
nuclear inclusions were identified that
are very similar to those described in
patients with mutations in PGRN that
are also known to cause FTLD-U (Mack-
enzie, 2007). Lastly, mice overexpressing
two different human VCP mutations
developed progressive muscle weak-
nessandpathology typical of IBM (Custer
et al., 2010). They also developed behav-
ioral abnormalities and brain pathology
similar to FTLD and multiple bony lesions
similar to Paget’s disease. Striking evi-
dence of cytoplasmic TDP-43 aggrega-
tion was evident in myocytes and nuclear
clearing in neurons in the frontal cortex
and motor neurons in the spinal cord. In
all of these studies, there is no evidence
that VCP itself accumulates or is directly
toxic. Instead the mutations appear to
cause a dominant-negative effect on the
wild-type protein.
VCP is a highly conserved member of
the AAA+ ATPase family as knockout is
lethal from yeast to mice (reviewed in Ju
and Weihl, 2010). It is highly expressed in
all tissues where it has a variety of cellular
functions including protein homeostasis
through the ubiquitin proteasome system
(UPS) and autophagy pathways. Previ-
ously, it was thought that these two path-
ways worked independently but VCP
appears to be integral to both. Overex-
pression of IBMPFD-related VCPmutants
leads to TDP-43 mislocalization from the
nucleus to the cytoplasm of transfected
cells and transgenic mice (Ju et al.,
2009). Similar events are observed whenDecember 9, 2010 ª2010 Elsevier Inc. 813
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the chronic administration of bafilomycin
A or chloroquine in cells and in mice. This
led the authors to conclude that the
pathology observed in IBMPFD is due to
disruption of autophagy and that TDP-43
is a major substrate. One of the markers
of proteins targeted for degradation by
the autophagy pathway is p62, and it is
interesting to note that p62-positive inclu-
sions are more abundant than ubiquiti-
nated inclusions in ALS. So is TDP-43
merely a sticky protein that fails to be
degraded by the UPS and autophagy
pathways, or might it be mechanistic in
initiating neurodegeneration?
More than 38 mutations have been
identified in TARDBP in FALS and SALS
cases (Lagier-Tourenne et al., 2010).
Overexpression of wild-type TDP-43 and
many mutants or knockdown of endoge-
nous protein leads to neurodegeneration.
The fact that TDP-43 mislocalization of
TDP-43 is seen following VCP and PGRN
mutations adds further evidence that
TDP-43 is mechanistic in ALS and FTLD
(see Figure 1). In addition to FUS, motor
neurons appear to be particularly suscep-
tible to defects in other RNA-processing
genes as evidenced by several auto-
somal-recessive syndromes (reviewed in
van Blitterswijk and Landers, 2010).
Homozygous deletions in SMN1,
encoding a protein involved in RNA
splicing and trafficking, cause spinal mus-
cular atrophy (SMA),while pointmutations
inGLE1, essential for the nuclear export of
mRNA, cause a fetal motor neuronopathy
called lethal congenital contracture
syndrome (Nousiainen et al., 2008). Muta-814 Neuron 68, December 9, 2010 ª2010 Elstions in IGHMBP2, which is involved in
translation, cause SMA and respiratory
distress (SMARD1). Furthermore, variants
in ELP3, which is involved in RNA tran-
scription and processing, andANG, which
canact asa tRNARNase, havebeenasso-
ciated with susceptibility to sporadic ALS.
The frequency of VCP mutations in the
study by Johnson et al. (2010) is around
2% of FALS, which is similar to that seen
for TARDBP and FUS. The number of
patients with mutations is still small, and
screening should be undertaken in larger
FALS and SALS cohorts in order to
replicate this finding and establish the
frequency in different populations. The
clinical message is that features of
IBMPFD should be sought in familial ALS
patients and VCP screening conducted
whether or not serum alkaline phospha-
tase is raised. A detailed comparative
exploration of TDP-43 pathology and the
role of autophagy in cellular and animal
models exploiting TARDBP, VCP, and
PGRN mutations may help identify a
common pathway linking neurodegenera-
tion in ALS and FTLD.REFERENCES
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